Regulatory watch: Challenges in drug development for central nervous system disorders: a European Medicines Agency perspective

Nat Rev Drug Discov. 2016 Nov 29;15(12):813-814. doi: 10.1038/nrd.2016.237.

Authors

Florence Butlen-Ducuing¹, Frank Pétavy¹, Lorenzo Guizzaro¹, Malgorzata Zienowicz¹, Manuel Haas¹, Enrica Alteri¹, Tomas Salmonson², Emmanuelle Corruble³

Affiliations

¹ European Medicines Agency, 30 Churchill Place, Canary Wharf, London E14 5EU, UK.
² Medical Products Agency, SE-751 03 Uppsala, Sweden, and is Chair of the CHMP.
³ INSERM UMR 1178, Univ Paris Sud, Service de Psychiatrie, Hôpital Bicêtre, Assistance Publique Hôpitaux de Paris, Le Kremlin Bicêtre, France.

PMID: 27895328
DOI: 10.1038/nrd.2016.237

No abstract available

MeSH terms

Central Nervous System Agents / pharmacology
Central Nervous System Agents / therapeutic use*
Central Nervous System Diseases / drug therapy*
Drug Approval*
Drug Design*
European Union
Government Agencies
Humans

Substances

Central Nervous System Agents